Shortening antibiotic treatment for endocarditis
Accelerated Treatment of Endocarditis
This study is testing if a shorter course of antibiotics can safely treat patients with left-sided infectious endocarditis, compared to the usual longer treatment, to see if it helps them recover faster.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 475 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Herlev Hospital Academic / other |
| Locations | 2 sites (Copenhagen and 1 other locations) |
| Trial ID | NCT05144399 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the safety and effectiveness of an accelerated antibiotic treatment for patients with left-sided infectious endocarditis. By utilizing individual patient data, such as clinical and paraclinical responses, the study aims to personalize treatment duration, potentially reducing the standard 4-6 weeks of hospitalization. The trial will enroll approximately 475 patients, focusing on those infected with specific bacteria like Streptococci and Staphylococcus aureus. Participants will be randomly assigned to either the accelerated treatment or the standard treatment length.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old admitted with left-sided infectious endocarditis and who have received less than 14 days of relevant antibiotic treatment.
Not a fit: Patients with known immune incompetency or those experiencing a relapse of endocarditis within the last six months may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce hospitalization time and associated risks for patients with endocarditis.
How similar studies have performed: While there is ongoing research in personalized treatment approaches, this specific method of shortening endocarditis treatment based on individual responses is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Admitted with left-sided infectious endocarditis (duke criteria) * \< 14 days of relevant antibiotic treatment for endocarditis * One of the following bacteria: Streptococci, enterococcus faecalis, staphylococcus aureus * \> 18 years old Exclusion Criteria: * Known immune incompetency, * Relapse endocarditis with 6 months, * Unable to give informed concent
Where this trial is running
Copenhagen and 1 other locations
- Rigshositalet — Copenhagen, Denmark (Recruiting)
- Herlev Hospital — Herlev, Denmark (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.